anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the group submitted to the mental Practice the sessions will be individualized and occur in tranquil room after physical therapy (Same performed with the control group). During the mental practice the patient will be guided to stand, where he will be requested initially to identify and to sequencer the necessary joints for the accomplishment of an only step, being they:flexion of the thigh and leg rights, extension of the right leg more dorsiflexed of the right foot; touch of the heel and discharge of weight of the right foot and inclined body to the front. The sessions occur two times per week during 15 minutes.
After completing 12 months observation of usual practices of menstrual hygiene management, all participants will be provided reusable menstrual cups that can be worn during sex. The menstrual cup training is comprised of a 2 hour group session that covers basic information on reproductive health, menstrual health, and menstrual hygiene, cup use (insertion/removal), storage, cleaning. In the first three months after intervention delivery, there are monthly phone calls to assess usage and for trouble shooting. There are 12 months of observation in the menstrual cup arm, with Bacterial vaginosis (BV) and vaginal microbiome (VMB) assessment at the beginning of the 12-month period, at 6 months, and at 12 months. Sexually transmitted infection (STI) is measured at the beginning of the 12- month intervention period, and then at 12 months.
Hypoactive Sexual Desire Disorder (HSDD) is a very common syndrome in adult women and men, characterized by a severe deficiency in the desire for sexual activity, causing marked distress. There is some data that androgens such as testosterone have some beneficial effect in this condition. DHEA is a neurosteroid that is metabolized into testosterone and estrogen, both of assumed importance in the regulation of sexual libido. The direct involvement of DHEA in the regulation of sexual function is unknown, however, DHEA treatment improved libido in midlife-onset depressed subjects. In this study, we will treat women and men suffering from HSDD with DHEA. The study's first objective is to determine the effect of DHEA treatment on sexual libido in menopausal women and both young and mid-aged men. The secondary objective is to compare baseline measures of DHEA, androgens, and other neurosteroids, in individuals with HSDD to controls. Furthermore, we will investigate possible correlations between plasma and urine levels of several neurosteroids and change in measures of libido. Fifty women and men diagnosed with HSDD will be treated with either 100 mg of DHEA or placebo for 6 weeks, in a double-blind, placebo-controlled study. Outcome measures will include several 17-Ketosteroids, DHEAS and bioavailable testosterone. Psychological outcome measures will include sexual function, mood and well-being. Twenty controls without HSDD will also be recruited to determine and compare their baseline levels of neurosteroids.
Participants will be randomized to receive single oral or 2 oral doses for divided daily doses of BIIB091 on Day 1 of Period 1, in fasted state or single oral dose of BIIB091 on Day 1 of Period 1, in fed state. Participants will receive single oral dose of BIIB091 on Day 1 of Period 2, in fasted state. Participants will receive single or two divided oral dose(s) of BIIB091 on Day 1 of Periods 3 and 4, in fasted or fed state. There will be a minimum 7-day washout between Day 1 of each study period.
Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
PROBLEM TO BE SOLVED: To increase effects on cosmetics in a coating agent composition to be used for a tooth manicure applied to each tooth.SOLUTION: The coating agent composition for a tooth manicure comprises: shellac; ester gum; a thickening-coating agent; a surfactant; and ethanol as the main components. As the ester gum, pentaerythritol or glycerol ester of resin acid is used. As the thickening-coating agent, an acrylic acid-acrylamide-ethyl acrylate copolymer is used. As the surfactant, a water-insoluble surfactant is used, and is selected from polyhydric alcohol having three or more hydroxy groups and the dehydrated condensates thereof and the oil-soluble esters of resin acid containing ≥8C fatty acid and/or abietic acid, neoabietic acid or the like. Further, one or more kinds selected from pigment, a medicinal components having cariostatic action and bactericide-antimicrobial agents are added as auxiliary components. The pigment is selected from titanated mica, titanium oxide, hydroxyapatite and silica-coated titanium oxide.
In pre-marketing trials involving over 3,210 patients, accidental or intentional overdose of iloperidone was documented in 8 patients ranging from 48 mg to 576 mg taken at once and 292 mg taken over a 3-day period. No fatalities were reported from these cases. The largest confirmed single ingestion of iloperidone was 576 mg; no adverse physical effects were noted for this patient. The next largest confirmed ingestion of iloperidone was 438 mg over a 4-day period; extrapyramidal symptoms and a QTc interval of 507 msec were reported for this patient with no cardiac sequelae. This patient resumed iloperidone treatment for an additional 11 months. In general, reported signs and symptoms were those resulting from an exaggeration of the known pharmacological effects (e.g., drowsiness and sedation, tachycardia and hypotension) of iloperidone.
The invention belongs to the field of daily-use chemicals and specifically relates to a moisturizing gel and its preparation method. The moisturizing gel comprises the following ingredients, by weight, 10-15 parts of glycerin, 5-12 parts of castoroil, 9-16 parts of lanolin, 20-28 parts of almond flour, 1-6 parts of citric acid, 15-28 parts of cucumber, 5-10 parts of cetyl ethyl hexanoate, 6-9 parts of radix angelicae and 50-69 parts of water. According to the invention, glycerin, castoroil, lanolin, almond flour, citric acid, cucumber, cetyl ethyl hexanoate, radix angelicae and water are compounded reasonably. Each raw material is safe and non-irritating to skin. Citric acid can promote nutrient substances in lanolin, cucumber and radix angelicae and water to rush through pores and enter the inside of skin, so as to lock moisture in skin. The finished product can effectively keep facial skin moist and elastic and also has an excellent effect of decreasing spots. The preparation method is simple and easy to operate, has mild preparation conditions and is suitable for large-scale popularization and application.
Myocardial Infarction (MI) is a leading cause of death worldwide. Metabolic modulation is a promising therapeutic approach to prevent adverse remodeling after MI. However, whether material-derived cues can treat MI through metabolic regulation is mainly unexplored. Herein, a Cu2+ loaded casein microgel (CuCMG) aiming to rescue the pathological intramyocardial metabolism for MI amelioration is developed. Cu2+ is an important ion factor involved in metabolic pathways, and intracardiac copper drain is observed after MI. It is thus speculated that intramyocardial supplementation of Cu2+ can rescue myocardial metabolism. Casein, a milk-derived protein, is screened out as Cu2+ carrier through molecular-docking based on Cu2+ loading capacity and accessibility. CuCMGs notably attenuate MI-induced cardiac dysfunction and maladaptive remodeling, accompanied by increased angiogenesis. The results from unbiased transcriptome profiling and oxidative phosphorylation analyses support the hypothesis that CuCMG prominently rescued the metabolic homeostasis of myocardium after MI. These findings enhance the understanding of the design and application of metabolic-modulating biomaterials for ischemic cardiomyopathy therapy.
XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
RECOMMANDATIONS for hepatitis A vaccination is the same for HIV-infected patients than for general population. However, immunogenicity induced with 2 doses of anti-HAV vaccine is lower in HIV-infected patients. The primary objective of the study is to compare the immunogenicity (percentage of patients with anti-HAV antibodies \> 20 mUI/ml at month 7) of 2 strategies (2 doses at months 1 and 6, versus 3 doses at months 1, 2 and 6)of anti-HAV vaccine in HIV-1 infected patients co-infected with HBV and/or HCV with CD4 cell count between 200 and 500/mm3. The second objectives are to compare mean anti-HAV antibodies titers obtained with the 2 strategies, the durability of the seroprotection 12 months after the end of vaccination, and the safety. The PARAMATERS than may have an effect on the immune response will be evaluated.

This open, prospective, study have included 99 patients, aged from 18 to 55 years old. Patients were randomized to receive 2 or 3 doses of HAVRIX 1440 UI intramuscularly at week O, 4, and 24 or week 0, and 24. Clinical and biological safety is evaluated after each immunisation and blood samples for serological evaluation taken at week -4, 4, 8, 24 and 28 for immunogenicity and week 72 for long term analysis
PROBLEM TO BE SOLVED: To obtain a film which is useful for a poultice and can cause a clinically effective amt. of a drug to be absorbed while hardly causing contact dermatitis by selecting a polyester film which mainly comprises a polyester contg. specific spherical silica particles and of which an air layer at the surface has a specified average thickness. SOLUTION: This polyester film selected mainly comprises a polyester (e.g. polyethylene terephthalate) contg. spherical silica particles having a length/width ratio of 1.0-1.2, pref. 1.0-1.15, still pref. 1.0-1.1, and has such characteristics that the average thickness of an air layer at the film surface is 2.0-5.0μm, pref. 2.2-4.0μm, that the relative standard deviation of the size of the silica particles is 0.5 or lower, and that the average size of the silica particles is pref. 0.3-4μm.
The primary objectives of any high-volume surgery department should be patient safety, block time utilization and operating room efficiency. Reducing preparation time in the OR prior to actual surgery can improve operating room efficiency and utilization, but only if patient safety can be maintained. With this goal, this study evaluated a novel skin preparation technique using a device named ULTRAPREP™, a sterile, medical-grade plastic bag that is applied to the upper or lower extremity in the pre-operative holding area which allows for skin disinfection outside the OR (referred to as "disinfection bag"). The study compared preparation times required in the OR and antiseptic efficiency (through Colony Forming Units (CFU) counts) for traditional methods versus using the disinfection bag on a total of 115 patients undergoing podiatric or orthopedic surgeries (upper and lower extremities) in one hospital. The disinfection bag reduced skin preparation time in the OR from 16.8±3.5min to 10.9±2.7min, which was a 35.2% reduction, and was statistically significant (p<0.01). Skin antisepsis met safety standards of <15 CFUs for all cases regardless of preparation type at 48h and 72h. There was no statistical difference in CFU levels between the traditional and disinfection bag methods at 48h or 72h (p>0.11). Therefore, ULTRAPREP™ has shown the ability to decrease operating room time while keeping surgical site infection rates to a minimum. Minimizing activities in the OR optimizes use of this costly resource and brings overall savings to the surgery department.
The invention provides a daochi powder formula granule. The daochi powder formula granule consists of co-decoction extracts of dried rehamnnia root, raw liquorice, caulis akebiae and bamboo leaves. The invention further provides a preparation method, a use and a detection method of the daochi powder formula granule. The daochi powder formula granule disclosed by the invention keeps all characteristics of the daochi powder, has active ingredients, nature and flavor, channel tropism, major functions and effect which are consistent with those of conventional daochi powder, and also has a plurality of advantages of less dosage, quick effect, complete components, accurate curative effect and the like, does not need decoction, can be directly taken, and is safe and sanitary and convenient to carry and store. The preparation method of the daochi powder formula granule is simple, low in cost and suitable for industrial production. The identification method adopted by the detection method of the daochi powder formula granule has strong specificity, high content measurement accuracy, good repeatability, and the detection method can be used for effectively controlling the quality of the product during a product production process, so that the clinical effect and the safety of the daochi powder formula granule are ensured.
PROBLEM TO BE SOLVED: To provide a medicine information managing device which prevents medical faults by preventing a patient from being dosed with wrong medicines and improve the efficiency of operation for preparing medicines that the patient is dosed with. SOLUTION: When a check sheet is printed, a patient is specified and information on medicines that the specified patient is dosed with and instruments is extracted (S1418) and printed (S1419). When a prescription is changed or a label is printed, an object patient of the change is specified (S1411). When the prescription of the specified patient is changed, the prescription is changed (S1413). When a name label is printed, information to be printed is extracted (S1414) from the information specified (S1411) and printed (S1415). When a management or submanagement label is printed, information to be printed is extracted (S1416) from the information specified (S1411) and printed (S1417).
PROBLEM TO BE SOLVED: To obtain the subject new compound having suppressing actions on the production of interferon γ from active lymphocytes and useful as an active ingredient of a therapeutic agent for autoimmune diseases. SOLUTION: This compound is represented by formula I [R1 to R4 are each H a halogen, amino, an acyl, an acylamino, hydroxyl group, a (substituted)lower alkyl or a (substituted)lower alkoxy], e.g. a compound represented by formula II. For example, the compound represented by formula I is obtained by condensing the corresponding hydroxybenzaldehyde with 2,6-diisopropylamine with an acid (e.g. sulfuric acid), providing bis(4-amino-3,5-diisopropylphenyl)- hydroxyphenylmethane and then oxidizing the resultant compound. The above compound is useful as an active ingredient of a medicine for treatment and/or prophylaxis of autoimmune diseases caused by an abnormality in the immune system, e.g. multiple sclerosis or rheumatism. The daily dose of the medicine for an adult is preferably 1-3,000 mg.
Parents and children selected for the Training group will be lent a laptop for the duration of the at-home training, and assisted in opening the video game training exercise. Parents and children will be shown the game's operation and controls, including a home visit to the family's house to help them establish the game as part of routine. Parents will be asked to engage their children in the video game training exercise (on the laptop) for a minimum of 20 minutes, 3 times a week, for 4 weeks. The app will log all responses as well as time spent playing.
BACKGROUND: We report a rare case of new onset autoimmune adrenal insufficiency in childhood, presenting with severe shock requiring mechanical circulatory support. In the current era of readily available imaging, laboratory and other diagnostic investigations, medical history and careful physical exam can often provide valuable diagnostic information for timely therapy.
CASE PRESENTATION: A 7-year-old boy with a history of mild intermittent asthma, presented with severe cardiogenic shock requiring extracorporeal membrane oxygenation (ECMO). Bronzing of his entire body was noted on physical exam. Stress dose hydrocortisone was given for suspected adrenal insufficiency. After weaning from ECMO and extensive rehabilitation, the patient recovered and was discharged home.
CONCLUSION: Primary adrenal insufficiency (PAI) should be considered in the context of physical exam and laboratory findings, even in the presence of circulatory shock.
PURPOSE: To compare functional and morphological outcomes of Subthreshold Laser (STL) and Oral Spironolactone (SPR) in treating chronic central serous chorioretinopathy (CSCR).
METHODS: This is a retrospective observational study. Treatment-naïve patients with chronic CSCR treated with STL or SPR were included, and data was reviewed at baseline, 1, 3, 6 and 12-month follow-up. Main outcome measures were changes in Central Macular Thickness (CMT) and Subretinal Fluid (SRF) height, and complete resolutions of SRF. Sub-analysis based on retinal pigmented epithelium (RPE) status at baseline was performed.
RESULTS: 47 and 47 patients received STL and SPR, respectively. At all timepoints, both treatments significantly improved CMT and SRF (p < 0.05). No significant changes in best corrected visual acuity (BCVA) were recorded and no significant differences between treatment groups were present at each corresponding follow-up. Complete resolution of SRF was achieved in 29% and 36% of patients treated with STL or SPR, respectively, at 12-months follow up. Eyes treated with STL and intact RPE showed significant SRF decrease at 6 months and significantly better BCVA at 1, 3 and 6 months compared to eyes with disrupted RPE layer (p < 0.05). In both treatment groups, intact RPE was associated with a higher rate of complete SRF resolutions, with 43% vs 13% in the STL group and 50% vs 26% in the SPR group.
CONCLUSION: STL and SPR are effective treatments for chronic CSCR. Greater resolution of subretinal fluid was observed in eyes with intact RPE, hence both treatments should be initiated in the earlier stages of the disease.
Parkinson's disease (PD) is an age-related chronic neurological condition characterized by progressive degeneration of dopaminergic neurons and the presence of Lewy bodies, primarily composed of alpha-synuclein and ubiquitin. The pathophysiology of PD encompasses alpha-synuclein aggregation, oxidative stress, neuroinflammation, mitochondrial dysfunction, and impaired autophagy and ubiquitin-proteasome systems. Among these, the Keap1-Nrf2 pathway is a key regulator of antioxidant defense mechanisms. Nrf2 has emerged as a crucial factor in managing oxidative stress and inflammation, and it also influences ubiquitination through p62 expression. Keap1 negatively regulates Nrf2 by targeting it for degradation via the ubiquitin-proteasome system. Disruption of the Nrf2-Keap1 pathway in PD affects cellular responses to oxidative stress and inflammation, thereby playing a critical role in disease progression. In addition, the role of neuroinflammation in PD has gained significant attention, highlighting the interplay between immune responses and neurodegeneration. This review discusses the various mechanisms responsible for neuronal degeneration in PD, with a special emphasis on the neuroprotective role of the Nrf2-Keap1 pathway. Furthermore, it explores the implications of inflammopharmacology in modulating these pathways to provide therapeutic insights for PD.
Ferric complexes of hydrogenated dextrans for parenteral and/or enteral treatment of iron-deficiency in human and/or veterinary medicine. Prepared by mixing precipitated, washed and filtered iron hydroxide, in the moist state, with dry hydrogenated dextran and, optionally, citric acid or its alkali metal salts to give a homogeneous mass, basifying this with NaOH soln., heating the stirred mixture until the end-product is water-soluble, cooling the resulting soln., filtering, and treating the filtrate with an ion-exchanger to remove excess NaOH. Teh hydrogenated dextran used pref. has a reducing power (determined by the Samogyi method) of 0.02-3.0 glucose gramme equvs./100 g. Advantages are that the product has low toxicity and is cheap and easy to make (colloidal ferric hydroxide is not needed, dialysis and electrodialysis are not employed, and materials are used in high concns. so that the working volume of the apparatus used is reduced). The optional use of citric acid or its alkali metal salts reduces the heating time required to make the complex water-soluble, improves the physical properties of the soln. obtained and minimise the fall in pH when the product is treated with ion-exchanger to remove excess NaOH.
Disitamab Vedotin: 2.0mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Cardonilimab: 6mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.
PURPOSE:A medicinal pharmaceutical, containing 1-aminoadamantane or a salt thereof as an active constituent, and effective for cerebral infraction, cerebral hemorrhage, subarachnoid hemorrhage, etc., particularly improving the depressive mood of patients with the sequela thereof and normalizing and recovering the act and behavior thereof in the daily life. CONSTITUTION:A pharmaceutical containin 1-aminoadamantane or a salt thereof, e.g. 1-aminoadamatane hydrochloride, nitrate or sulfate, as an active constituent. A tablet containing 50mg or 100mg 1-aminoadamantane hydrochloride in one tablet or fine granular pharmaceutical containing 100mg 1-aminoadamantane hydrochloride in one g fine granule may be used as the pharmaceutical. However, a water-soluble soft capsule pharmaceutical packed with 100mg active constituent and an adjuvant in one capsule or a suppository prepared by melting 100mg active constituent with a base, e.g. a fatty acid glyceride, is used conveniently for the purpose.
Despite the already dire impact of pancreatic cancer, a growing subset of patients with obesity exhibits an amplified risk of disease and worse outcomes. Mouse models have revealed that obesity is distinctly pathogenic, accelerating pancreatic ductal adenocarcinoma (PDAC) progression and inducing increased desmoplasia and myeloid cell infiltration in the tumor microenvironment. However, whether and how obesity-countering interventions, such as exercise, reverse the protumorigenic effects of obesity is incompletely understood. In this issue of Cancer Research, Pita-Grisanti and colleagues investigate the impact of physical activity (PA) in disrupting obesity-driven PDAC. Employing a variety of sophisticated models, including autochthonous genetically engineered mice, orthotopic syngeneic allografts, high-fat diet-induced obesity, and PA interventions in mice and humans, the authors found that PA impedes PDAC development in obese mice but does not impact the growth of advanced tumors. These antitumor effects correlated with reduced inflammation and fibrosis in the tumor microenvironment, a decline in high-fat diet-induced circulating inflammatory cytokines, and an increase in the IL15 signaling axis in white adipose tissue. Although adipose-targeted IL15 therapy was effective in suppressing advanced tumor growth in lean mice, obese mice were resistant to its therapeutic benefits. Together, the findings argue that PA delays obesity-driven early PDAC progression, implicating the preferential benefit of exercise as a preventative strategy. They further identify changes in obesity-associated local and systemic cytokine production as a possible mechanism for the antitumor effects of PA and help define context-specific determinants of response for emerging IL15-based immunotherapies. See related article by Pita-Grisanti et al., p. 3058.